Crushing of dolutegravir fixed-dose combination tablets increases dolutegravir exposure | Zendy

Marieke Roskam-Kwint | Zendy; Pauline Bollen | Zendy; Angela Colbers | Zendy; Marjolijn Duisenberg-van Essenberg | Zendy; Veroniek E. M. Harbers | Zendy; David M. Burger | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Crushing of dolutegravir fixed-dose combination tablets increases dolutegravir exposure

Author(s) -

Marieke Roskam-Kwint,

Pauline Bollen,

Angela Colbers,

Marjolijn Duisenberg-van Essenberg,

Veroniek E. M. Harbers,

David M. Burger

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky191

Subject(s) - dolutegravir , medicine , virology , pharmacology , human immunodeficiency virus (hiv) , antiretroviral therapy , viral load

If HIV patients are unconscious or cannot swallow tablets for other reasons, antiretroviral medication is crushed and dissolved prior to administration. Crushing can alter drug exposure, possibly leading to treatment failure, development of resistance or toxicity. Currently, there is no information about crushing of the branded fixed-dose combination of dolutegravir/abacavir/lamivudine (Triumeq®, referred to as TRI); therefore, crushing of TRI is not recommended.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research